Causal plasma metabolites for breast cancer risk: a two-sample Mendelian randomization study with colocalization evidence
This study establishes carnitine C14 as a novel protective biomarker and epiandrosterone sulfate as a risk biomarker for breast cancer, with colocalization evidence supporting their therapeutic targeting. The metabolic risk profile provides a foundation for precision prevention strategies.
Authors
- Hanghang Chen
- Xu-Feng Cheng (ORCID: https://orcid.org/0000-0001-5826-9414)
- Zepeng Wang (ORCID: https://orcid.org/0000-0002-7411-4663)
- Yueyuan Xu (ORCID: https://orcid.org/0000-0002-8571-0700)
Institutions
- Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine (CN)
- First Affiliated Hospital of Henan University of Traditional Chinese Medicine (CN)
- First Affiliated Hospital of Henan University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1007/s12672-025-03721-7
- Primary Topic
- Genetic Associations and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Breast Cancer Research Foundation
- Ovarian Cancer Research Fund
- Genome Canada
- Gray Foundation
- Fondation du cancer du sein du Québec
- Government of Canada
- Cancer Research UK
- European Commission
- National Institutes of Health
- Canadian Institutes of Health Research